StreetInsider.com News Articles

Canaccord Reiterates Hold Rating on Veracyte, Inc (VCYT)

Tue, 02 Jun 2026 06:53:13 -0400

Canaccord analyst Kyle Mikson reiterated a Hold rating and $42.00 price target on Veracyte, Inc (NASDAQ: VCYT).

The analyst commented: "We reiterate our HOLD rating on Veracyte (VCYT) shares and maintain our price target at $42. Before the market open on Monday, June 1, VCYT hosted a conference call during the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting to review the results for its ENZAMET (Decipher) and OPTIMA (Prosigna) studies. Decipher and Prosigna demonstrated they could be used to predict chemo benefit for metastatic prostate cancer and early-stage, ER-positive HER2-negative breast cancer patients, respectively. ENZAMET results could help drive

Wolfe Research Assumes Veracyte, Inc (VCYT) at Outperform

Mon, 01 Jun 2026 16:26:05 -0400

(Updated - June 1, 2026 4:26 PM EDT)

Wolfe Research analyst Mike Polark assumes coverage on Veracyte, Inc (NASDAQ: VCYT) with a Outperform rating and a price target of $55.00.

The analyst comments "We rate VCYT shares Outperform and have a $55 price target. Our $55 price target represents 7 times 2026 revenue and 6 times 2027 revenue. This input is ~in-line with a wider set of specialty diagnostics peers trading at median/average 6x/7x 2026 revenue. Versus its own history, a 6x revenue multiple input is ~in-line with VCYT’s short- and long-term averages. VCYT is in a more mature chapter of its

Wolfe Research Assumes Veracyte, Inc (VCYT) at Outperform

Mon, 01 Jun 2026 16:26:05 -0400

(Updated - June 1, 2026 4:26 PM EDT)

Wolfe Research analyst Mike Polark assumes coverage on Veracyte, Inc (NASDAQ: VCYT) with a Outperform rating and a price target of $55.00.

Veracyte, Inc (VCYT) PT Raised to $57 at Needham

Mon, 01 Jun 2026 11:07:00 -0400

(Updated - June 1, 2026 11:07 AM EDT)

Needham analyst Mike Matson raised the price target on Veracyte, Inc (NASDAQ: VCYT) to $57.00 (from $48.00) while maintaining a Buy rating.

The analyst commented: "This morning, VCYT hosted a webinar discussing the results from the OPTIMA trial. VCYT reiterated that Prosigna now has Level 1A evidence of chemotherapy benefit prediction, and highlighted that the OPTIMA study was the first study with definitive data outlining chemotherapy selection in high-risk, node-positive, premenopausal women with breast cancer. VCYT is launching Prosigna in the US (~225,000 patients and ~$700M addressable market) on 6/8/26 and we expect it

Veracyte, Inc (VCYT) PT Raised to $57 at Needham

Mon, 01 Jun 2026 11:07:00 -0400

(Updated - June 1, 2026 11:07 AM EDT)

Needham analyst Mike Matson raised the price target on Veracyte, Inc (NASDAQ: VCYT) to $57.00 (from $48.00) while maintaining a Buy rating.

Veracyte launches Prosigna breast cancer test in US market

Mon, 01 Jun 2026 07:30:44 -0400

Veracyte Inc. (NASDAQ: VCYT) announced the U.S. commercial launch of its Prosigna Breast Risk of Recurrence test for patients with early-stage hormone-receptor positive breast cancer. The genomic test will be available for ordering starting June 8, 2026.

The Prosigna test determines a patient's risk of recurrence score and estimates the 10-year probability of distant recurrence in breast cancer patients. The test combines intrinsic subtypes and proliferation score with clinical factors to assess whether patients may benefit from chemotherapy or can safely receive endocrine therapy alone.

The announcement follows results from the OPTIMA trial presented at the ASCO Annual Meeting, which showed that

Veracyte launches Prosigna breast cancer test in US market

Mon, 01 Jun 2026 07:30:44 -0400

The announcement follows results from the OPTIMA trial presented at the ASCO Annual Meeting, which showed that

Veracyte launches Prosigna breast cancer test in US market

Mon, 01 Jun 2026 07:30:44 -0400

The announcement follows results from the OPTIMA trial presented at the ASCO Annual Meeting, which showed that

Veracyte launches Prosigna breast cancer test in US market

Mon, 01 Jun 2026 07:30:44 -0400

The announcement follows results from the OPTIMA trial presented at the ASCO Annual Meeting, which showed that

Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.